Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Meets all of the following conditions:~  * A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD)~ * Screening magnetic resonance imaging - proton density fat fraction (MRI-PDFF) with ≥ 8% steatosis~ * Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kPa~    * OR~ * A historical liver biopsy consistent with NASH and non-cirrhotic fibrosis~* Platelet count ≥ 100,000/mm\^3~* Creatinine Clearance (CLcr ) as calculated by the Cockcroft-Gault equation ≥ 60 ml/min~Key Exclusion Criteria:~* Pregnant or lactating females~* Alanine aminotransferase (ALT) \> 5 x upper limit of the normal range (ULN)~* Other causes of liver disease including autoimmune, viral, and alcoholic liver disease~* Cirrhosis of the liver~  * Prior history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding~* Body mass index (BMI) \< 18 kg/m\^2~* International normalized ratio (INR) \> 1.2 unless on anticoagulant therapy~* Total bilirubin \> 1 x ULN, except with diagnosis of Gilbert's syndrome~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Firsocostat 5 mg (Type: EXPERIMENTAL): Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
- Firsocostat 20 mg (Type: EXPERIMENTAL): Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
- Placebo (Type: EXPERIMENTAL): Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).